Kalvista Pharmaceuticals Inc:Leerink Partners下调评级至“与大盘持平”,目标价上调至27美元

美股速递
Apr 30

投资机构Leerink Partners宣布,将生物制药公司Kalvista Pharmaceuticals Inc的股票评级从“跑赢大盘”下调至“与大盘持平”。与此同时,该机构将其目标股价从原先的22美元显著上调至27美元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10